论文部分内容阅读
目的探讨Ⅰb~Ⅱb宫颈癌术前使用新辅助化疗的临床疗效。方法选择2013年1月至2015年3月治疗的52例Ⅰb~Ⅱb宫颈癌患者的临床资料进行回顾性分析。所有患者术前给予新辅助化疗治疗,评价患者的近期疗效以及手术根治率。结果 52例患者中37例进行1个化疗疗程,15例进行2个化疗疗程。完全缓解率为19.2%(10/52),部分缓解率为69.2%(36/52),总有效率为88.5%(46/52)。鳞癌的有效率显著高于腺癌(P<0.05)。46例行宫颈癌根治术治疗,根治率为88.5%。术后病理分级:Ⅰ级6例(13.0%),Ⅱ级36例(78.3%),Ⅲ级4例(8.7%)。无严重并发症发生。随访至2015年9月,手术根治治疗的46例患者均存活。结论术前新辅助化疗治疗Ⅰb~Ⅱb宫颈癌具有较高的根治率,尤其是鳞癌患者,能改善患者预后,且无严重并发症发生。
Objective To investigate the clinical efficacy of neoadjuvant chemotherapy for Ⅰb ~ Ⅱb cervical cancer before operation. Methods The clinical data of 52 patients with stage Ⅰb ~ Ⅱb cervical cancer who were treated from January 2013 to March 2015 were retrospectively analyzed. All patients were given neoadjuvant chemotherapy before surgery to evaluate the short-term efficacy and the rate of radical surgery. Results Among 52 patients, 37 patients underwent one chemotherapy course and 15 patients underwent two chemotherapy courses. The complete remission rate was 19.2% (10/52), the partial remission rate was 69.2% (36/52) and the total effective rate was 88.5% (46/52). The effective rate of squamous cell carcinoma was significantly higher than that of adenocarcinoma (P <0.05). 46 cases of radical resection of cervical cancer, the cure rate was 88.5%. Postoperative pathological grade: grade Ⅰ in 6 cases (13.0%), grade Ⅱ in 36 cases (78.3%), grade Ⅲ in 4 cases (8.7%). No serious complications occurred. All the 46 patients undergoing radical surgery survived until September 2015. Conclusion Preoperative neoadjuvant chemotherapy for Ⅰb ~ Ⅱb cervical cancer has a high cure rate, especially in patients with squamous cell carcinoma, can improve the prognosis of patients, and no serious complications.